Related Experiment Video
Updated: Jun 24, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
The antimicrobial resistance profile of Streptococcus pneumoniae
1International Scientific & Clinical Affairs, Vaccines, Wyeth Pharmaceuticals, La Défense, Paris, France. ReinerR@wyeth.com
Abstract:
Antibacterial resistance in pneumococci is increasing worldwide, primarily against beta-lactams and macrolides. Understanding the role played by molecular determinants of resistance, transformation and competence in the evolution of Streptococcus pneumoniae is important in addressing this trend. Data from the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study indicate that about 40% of pneumococci display multidrug-resistant phenotypes (resistance to three or more antibiotics), with highly variable prevalence rates observed in different countries. Alterations in the structure of six penicillin-binding proteins (PBPs) have been described in S. pneumoniae (1a, 1b, 2x, 2a, 2b and 3), enabling resistance to beta-lactam antibiotics. Mechanisms conferring macrolide resistance include resistance mediated through the erm(B) gene, which results in macrolide-lincosamide-streptogramin B resistance, or through the mef(A) gene, which encodes an antibiotic efflux pump. Another variant, mef(E), is also expressed in S. pneumoniae; both mef(A) and mef(E) variants are associated with strains belonging to serotype 14. In addition to the selection pressure resulting from misuse of antibiotics, widespread vaccination programmes may contribute to changing pneumococcal epidemiology. Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7), the rate of invasive pneumococcal disease due to PCV7 serotypes has declined significantly in many countries, but some countries have reported an increase in non-PCV7 serotypes. This phenomenon, termed 'replacement', is associated with certain pneumococcal serotypes or clones (e.g. serotype 19A). Whether novel 'vaccine escape recombinant' pneumococcal strains are emerging or changes in distribution are part of a secular cycle remains to be determined.
Insights
Antibacterial resistance in Streptococcus pneumoniae is rising globally, with 40% of strains showing multidrug resistance. Understanding resistance mechanisms and vaccine impacts is crucial for combating this trend.
Area of Science:
- Microbiology
- Epidemiology
- Molecular Biology
Background:
- Increasing global antibacterial resistance in Streptococcus pneumoniae, particularly to beta-lactams and macrolides.
- Understanding resistance determinants and evolution is key to addressing this public health challenge.
- The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study provides insights into resistance patterns.
Purpose of the Study:
- To investigate the molecular mechanisms and epidemiological trends of antibiotic resistance in Streptococcus pneumoniae.
- To analyze the impact of antibiotic use and vaccination programs on pneumococcal resistance and disease prevalence.
Main Methods:
- Analysis of data from the PROTEKT study on pneumococcal isolates.
- Identification of molecular determinants of resistance, including alterations in penicillin-binding proteins (PBPs) and specific resistance genes (erm(B), mef(A), mef(E)).
- Evaluation of epidemiological data related to antibiotic resistance and vaccine impact, including serotype replacement.
Main Results:
- Approximately 40% of pneumococci exhibit multidrug-resistant phenotypes, with significant international variation.
- Beta-lactam resistance is associated with alterations in six specific penicillin-binding proteins.
- Macrolide resistance is mediated by the erm(B) gene or the mef(A)/mef(E) genes, often found in serotype 14 strains.
- Pneumococcal conjugate vaccine (PCV7) introduction led to decreased disease from targeted serotypes but increased prevalence of non-PCV7 serotypes (e.g., 19A).
Conclusions:
- Molecular mechanisms like PBP alterations and specific resistance genes drive antibiotic resistance in Streptococcus pneumoniae.
- Vaccination strategies influence pneumococcal epidemiology, potentially leading to serotype replacement and the emergence of resistant strains.
- Continued surveillance and research are essential to manage evolving antibacterial resistance and vaccine-induced epidemiological shifts.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Atypical Pneumonia
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pneumonia I: Introduction

